https://pittplusme.org/study/1877
HM-TRIA-201 Study for NASH
This study is not currently recruiting. Please check back at a later time.
STUDY BASICS
Do you have nonalcoholic steatohepatitis (NASH)? You may be able to participate in a study to help test an investigational drug called HM15211 to see if it can safely be used to reduce liver inflammation in people with NASH. Eligible participants are 18-70 years old. This study involves about 21 visits over 15 months. Compensation provided.
IRB: 20200673
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH
AGE:
18-70
DURATION:
15 months
VISITS:
About 21 visits
LOCATION:
Kaufmann Building – Oakland & by Phone
COMPENSATION:
Up to $2,750
SHARE STUDY
MEET THE RESEARCHER
Mordechai Rabinovitz
Mordechai Rabinovitz, MD, is a Professor of Medicine in the Division of Gastroenterology, Hepatology, and Nutrition at the University of Pittsburgh. A graduate of Tel-Aviv University in Israel, Dr. Rabinovitz’s research interests include assessment and treatment of chronic viral hepatitis as well as developing new therapies for non-alcoholic fatty liver disease.